| DATE: October 2, 2025 |
| --- |
| **TOPIC** | **DISCUSSION/ACTION** | **FOLLOW-UP** |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a poll link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Strawpoll sent with these minutes.<https://strawpoll.com/BJnXV9EmOZv> |
| CPIC update and paper | Kelly Caudle presented a recent CPIC publication highlighting successes of CPIC over the past 12 years. <https://pubmed.ncbi.nlm.nih.gov/40678821/>. Slides posted with minutes on [CPIC member site.](https://cpicpgx.org/member-resources/conference-call-minutes/2025-cpic-conference-call-minutes/)  |  |
| Guidelines In-progress | Guidelines* *NAT2/*hydralazine-published!
* *TPMT-NUDT15/*thiopurines-submitting today!
* *CYP2D6/5-HT3s-*drafted; will circulate to members soon
* Antipsychotics-almost done with recommendations; started drafting
* *CYP3A/*tacrolimus-working on recommendations
* *DPYD/*fluoropyrimidines
* *UGT1A1/*irinotecan-evidence review underway
* *HLA* guideline-recruiting authors now

PCEPs* PCEP overview paper- in review
* *NAT2*-submitting paper soon (tables available online)
* *TPMT/NUDT15*-drafted; submitting soon
* *DPYD*-underway
* *CYP3A-*underway
* *SLCO1B1*-changes made to allele function table. See <https://cpicpgx.org/guidelines/cpic-guideline-for-statins/> for update notice and tables
 | Kelly will continue to update.To see the guidelines currently being developed go to: <https://cpicpgx.org/prioritization-of-cpic-guidelines/> |
| *CYP2D6/5-HT3*-antagonist Guideline  | Kelly Caudle, PharmD, PhD, St. Jude Children’s Research Hospital, presented on behalf of the authors. | Select slides posted to member site.<https://cpicpgx.org/member-resources/conference-call-minutes/2025-cpic-conference-call-minutes/>The guideline will be sent for CPIC review in the next month. |